Savara (SVRA) announced a $75M royalty funding agreement with funds managed by RTW Investments, LP, subject to FDA approval of MOLBREEVI. The royalty financing will become available upon FDA’s approval of MOLBREEVI, and satisfaction of certain customary conditions. Under the terms of the agreement, RTW will receive a tiered single digit percentage of annual net sales of MOLBREEVI in the U.S. for the treatment of autoimmune PAP, subject to a cap.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SVRA:
- 3 Best Stocks to Buy Now, 10/23/2025, According to Top Analysts
- Savara price target raised to $11 from $8 at Citizens JMP
- Savara promotes Wasfi to Chief Medical Officer
- Savara initiated with an Outperform at LifeSci Capital
- Savara’s MOLBREEVI: A Promising Solution for Autoimmune Pulmonary Alveolar Proteinosis with Blockbuster Potential